Industry Movers

This section covers strategic actions by the largest players in pharma, biotech, and contract research — but through a ‘tech+bio’ lens. We track how incumbents adapt, invest, and evolve in response to the rise of AI platforms, digital R&D, data infrastructure, and other frontier technologies reshaping life sciences.

Whether it be Eli Lilly offering access to AI models to third-party users, GSK tapping AI to improve clinical trials, or IQVIA launching a compact medical-reasoning LLM - these are more than business transactions. They signal how established life-science institutions are reengineering themselves around the future of biology as an information science.

For example, in How Big Pharma Adopts AI To Boost Drug Discovery, we explored how largest pharma companies are aligning with the AI wave — via partnerships, in-house capabilities, or strategic investments.

This category complements our deeper analytical reporting in Business Intelligence, as well as coverage of smaller companies in Biotech Ventures and enabling technologies in AI in Bio and Next-Gen Tools.